Dr Fabio Almeida's center in Tucson, AZ

T

his is the first site to open for this interesting clinical trial using both Zytiga (abiraterone) and Xofigo (radium 223).  

All men will receive Zytiga + prednisone.  Some men will receive Xofigo, some will receive placebo instead of Xofigo.

Clinic visits are every 4-weeks for six months during treatment.  

 

Basic Eligibility Criteria for this trial:

  • Castrate resistant (Testosterone less than 50 w/ rising PSA)

  • 2 or more bone metastases

  • NO lung, liver, or other soft tissue metastases

  • NO previous chemo

  • NO previous Zytiga (abiraterone)

  • NO previous Xofigo or Samarium

  • Little or no cancer pain

  • NO atrial fibrillation, Crohn's disease, or ulcerative colitis


Location:

Arizona Molecular Imaging
Tucson, AZ

Contact: 

Elisa Blackwell 602.331.1771

**

Other locations to follow - View this link at ClinicalTrials.gov **

Comment